Optiscan Launches InSpecta™ in US Veterinary Market After FDA Approval
Optiscan Imaging has begun commercial sales of its InSpecta™ microscopic imaging device in the US veterinary sector following FDA clearance, marking its first clinical device launch and a strategic expansion into a $15.87 billion market.
- First FDA-cleared clinical device launched in US veterinary market
- InSpecta™ enables real-time cellular imaging at point of care
- Launch showcased at AVMA Convention 2026 in California
- Establishes regulatory and commercial foothold for future products
- Targets growing US veterinary market valued at nearly US$16 billion
Optiscan’s First Clinical Device Hits US Veterinary Market
Optiscan Imaging Ltd (ASX:OIL) has crossed a pivotal threshold, launching its InSpecta™ microscopic imaging device commercially in the US veterinary healthcare sector. This follows the successful submission and acceptance of its regulatory dossier by the FDA’s Centre for Veterinary Medicine, clearing the way for sales in what is a substantial and expanding market.
The InSpecta™ launch is not just a product release; it represents Optiscan’s transition from a developer of medical imaging technology to a commercial-stage company with a tangible presence in the US. The device is being showcased this week at the American Veterinary Medical Association (AVMA) Convention in Anaheim, California, putting it directly in front of veterinarians, specialists, and industry decision-makers.
Bridging the Diagnostic Gap in Veterinary Care
InSpecta™ is purpose-built for veterinary medicine, delivering cellular-level imaging in real time at the point of care. Compact and portable, it suits a range of settings from specialist hospitals to mobile veterinary services. By providing immediate microscopic insight, the device aims to fill a critical gap between traditional clinical examination and slower, lab-based diagnostics.
This capability supports faster clinical decision-making, streamlines workflows, and opens new revenue opportunities by enabling practices to offer advanced imaging services in-house. The technology is built on Optiscan’s proprietary imaging platform, which boasts spatial resolution far exceeding that of standard medical CT or MRI.
Tapping into a US$15.87 Billion Market
The US veterinary services market was valued at approximately US$15.87 billion in 2024 and is projected to grow strongly over the coming years, driven by rising demand for advanced care, including management of complex conditions like cancer. Optiscan’s entry into this market is timely, addressing a clear unmet need for improved diagnostic tools that enhance clinical insight and operational efficiency.
By establishing a commercial foothold with InSpecta™, Optiscan is positioning itself to capture a slice of this lucrative sector while building a regulatory pathway that could accelerate future product approvals. The FDA submission for InSpecta™ not only unlocked market access but also enhanced the company’s regulatory expertise for upcoming filings.
Commercial and Strategic Implications
Optiscan CEO Dr Camile Farah highlighted the launch as a defining milestone, underscoring the device’s design specifically for the US veterinary market and its potential to deliver immediate clinical benefits. The launch validates the maturity of Optiscan’s imaging platform and sets a repeatable regulatory and commercial template for other products in its pipeline.
While the company has yet to disclose specific sales targets or pricing strategies for InSpecta™, the commercial rollout at AVMA Convention provides a critical platform to engage potential customers and accelerate adoption. This launch complements ongoing efforts in human healthcare imaging, including recent clinical milestones in breast cancer imaging and robotic surgery collaborations.
Bottom Line?
Optiscan’s InSpecta™ launch in the US veterinary market marks a crucial step into commercialisation, with regulatory clearance laying groundwork for future product expansion.
Questions in the middle?
- How quickly will veterinary practices adopt InSpecta™ and what impact will this have on Optiscan’s revenue?
- Can Optiscan replicate this regulatory and commercial success with its human healthcare devices?
- What pricing model and sales strategy will Optiscan deploy to capture market share in the competitive US veterinary sector?
